Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004494 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
A Phase 1 study of Sepsis and Respiratory Distress Syndrome, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT00004494 is a Phase 1 study of Sepsis and Respiratory Distress Syndrome that has completed, run by Stony Brook University. The registered enrollment target is 18 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00004494, a Phase 1 study of Sepsis and Respiratory Distress Syndrome, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
OBJECTIVES: I. Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with acute respiratory distress syndrome. II. Evaluate the safety and pharmacodynamic activity of this peptide in these patients.
Conditions Studied
Interventions
- DRUG vasoactive intestinal peptide
Study Locations (2)
New York
- Veterans Affairs Medical Center - Northport - Northport
- State University of New York Health Sciences Center - Stony Brook - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 1998-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004494
The ClinicalTrials.gov registry entry for NCT00004494 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower). The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which vasoactive intestinal peptide is the first listed.
NCT00004494 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00004494 about?
NCT00004494 is a clinical study titled "Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis". OBJECTIVES: I. Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with acute respiratory distress syndrome. II. Evaluate the safety and pharmacodynamic activity of this peptide in these patients.
What is the current status of trial NCT00004494?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 1998-09.
What conditions does trial NCT00004494 study?
This clinical trial studies the following conditions: Sepsis, Respiratory Distress Syndrome, Respiratory Distress Syndrome, Adult.
What interventions are being tested in trial NCT00004494?
The interventions under investigation include: vasoactive intestinal peptide (DRUG).
Who is sponsoring clinical trial NCT00004494?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004494 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention
RECRUITING · Phase 1
-
Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
ACTIVE NOT RECRUITING · Phase 1
-
Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance
COMPLETED · Phase 1
-
Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections
COMPLETED · Phase 1
-
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
COMPLETED · Phase 1
-
The APS Phenotyping Study
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.